This analysis indicates unrealized opportunities to reduce mortality in selected Veterans with T2D and CAD via increased use of GLP‐1RA and SGLT2i (Diabetes, Obesity and Metabolism)
Diabetes News
Tag: GLP‐1RA
Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon‐Like Peptide‐1 Receptor Agonist and Sodium‐Glucose Cotransporter‐2 Inhibitor Treatment in Type 2 Diabetes Mellitus
Treatment with GLP‐1RA and SGLT2i led to significant reductions in BP in patients with type 2 diabetes mellitus. Weight reduction was significantly and independently associated with BP reductions in GLP‐1RA treatment and SGLT2i treatment (JAHA)
Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis
Long‐acting GLP‐1RAs showed superiority in reducing HbA1c levels, body weight and waist circumference. SGLT‐2is showed reductions in blood pressure levels. This review provide essential evidence to guide treatment recommendations in the management of type 2 diabetes (Diabetes, Obesity and Metabolism)
Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
Given that black patients with type 2 diabetes were not well represented in CVSTs and such trials were underpowered to evaluate racial differences, it remains unclear whether GLP‐1RAs or SGLT‐2is would reduce cardiovascular risk in such patients, and additional studies targeting black patients are urgently needed (Diabetes, Obesity and Metabolism)
Do GLP‐1RAs and SGLT‐2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta‐analysis
While our review suggests that GLP‐1RAs and SGLT‐2is did not significantly reduce cardiovascular risk in black patients with type 2 diabetes, the available data are underpowered to examine this suggestion (Diabetes, Obesity and Metabolism)
Glycosmedia is also available as an App: